Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Kura Oncology, Inc. KURA

Healthcare  —  Biotechnology
10.76 (0.10) (0.92%) as of 25 Sep
Market cap
$977.7M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Kura Oncology, Inc. (KURA) Business Profile

Updated before January 2025

Company Overview

Kura Oncology, Inc. (NASDAQ: KURA) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of precision medicines for the treatment of cancer. Founded in 2014 and headquartered in San Diego, California, Kura Oncology focuses on targeting specific genetic and molecular drivers of cancer to develop innovative therapies. The company was co-founded by Troy Wilson, Ph.D., J.D., who also serves as the President and Chief Executive Officer. Under his leadership, Kura has established itself as a leader in precision oncology, leveraging cutting-edge science and a patient-centric approach to address unmet medical needs in oncology.

Kura’s leadership team includes experienced professionals with deep expertise in oncology drug development, clinical research, and commercialization. The company’s board of directors and scientific advisory board are composed of industry veterans and leading researchers who provide strategic guidance and scientific insights to drive innovation.

Core Business Segments

Kura Oncology’s core business revolves around the development of targeted therapies for cancer. The company’s pipeline is focused on small molecule inhibitors that address specific genetic mutations and molecular pathways associated with cancer progression. Key product categories include:

1. FTI (Farnesyl Transferase Inhibitors)

  • Tipifarnib: Kura’s lead product candidate, Tipifarnib, is a potent and selective farnesyl transferase inhibitor. It is being developed for the treatment of HRAS-mutant head and neck squamous cell carcinoma (HNSCC) and other solid tumors. Tipifarnib has shown promising clinical activity in patients with HRAS mutations, a subset of cancers with limited treatment options.

2. Menin Inhibitors

  • KO-539: This is a novel, orally bioavailable small molecule inhibitor of the menin-MLL (mixed-lineage leukemia) protein-protein interaction. KO-539 is being developed for the treatment of acute myeloid leukemia (AML) and other cancers driven by MLL rearrangements or NPM1 mutations. The drug is currently in clinical trials and has demonstrated encouraging early results.

3. Preclinical Programs

Kura is also advancing a pipeline of preclinical programs targeting other oncogenic drivers and pathways. These programs aim to expand the company’s portfolio and address additional cancer indications with high unmet medical needs.

Business Model

Kura Oncology operates as a research-driven biopharmaceutical company with a focus on precision oncology. The company’s business model is centered on:

  • Drug Discovery and Development: Kura invests heavily in research and development (R&D) to identify and develop targeted therapies for cancer. The company collaborates with academic institutions, research organizations, and industry partners to accelerate drug discovery.
  • Clinical Trials: Kura conducts rigorous clinical trials to evaluate the safety and efficacy of its drug candidates. The company’s clinical development strategy is designed to generate robust data to support regulatory approvals and commercialization.
  • Partnerships and Licensing: Kura seeks strategic partnerships and licensing opportunities to enhance its capabilities and expand its reach. These collaborations enable the company to leverage external expertise and resources while focusing on its core strengths.
  • Revenue Generation: As a clinical-stage company, Kura does not yet generate significant revenue from product sales. The company relies on funding from investors, partnerships, and grants to support its operations and advance its pipeline.

Strategic Direction

Kura Oncology is committed to advancing its pipeline of precision medicines and delivering transformative therapies to cancer patients. The company’s strategic priorities include:

  • Advancing Clinical Programs: Kura aims to complete the clinical development of Tipifarnib and KO-539, with the goal of securing regulatory approvals and bringing these therapies to market.
  • Expanding the Pipeline: The company is actively exploring new targets and pathways to develop additional drug candidates. Kura’s preclinical programs are focused on addressing emerging opportunities in oncology.
  • Global Expansion: Kura plans to expand its presence in key markets worldwide, leveraging partnerships and collaborations to reach more patients.
  • Sustainability Goals: While not explicitly stated, Kura’s focus on precision medicine aligns with broader sustainability goals by reducing the burden of ineffective treatments and improving patient outcomes.

Competitive Landscape

Kura Oncology operates in a highly competitive biopharmaceutical industry, where it faces competition from both established companies and emerging players. Key competitors include:

  • Mirati Therapeutics: Focused on targeted oncology therapies, particularly KRAS inhibitors.
  • Blueprint Medicines: Specializes in precision therapies for genomically defined cancers.
  • Relay Therapeutics: Develops small molecule therapies targeting protein motion.
  • Revolution Medicines: Focused on RAS pathway inhibitors.
  • Other Large Biopharma Companies: Companies like Novartis, Roche, and Pfizer also compete in the oncology space with broader portfolios and significant resources.

Kura differentiates itself through its focus on specific genetic mutations and its commitment to precision medicine.

Risk Factors

Kura Oncology faces several risks that could impact its business and operations:

  • Regulatory Risks: The success of Kura’s drug candidates depends on obtaining regulatory approvals, which can be uncertain and time-consuming.
  • Clinical Trial Risks: Clinical trials may fail to demonstrate safety and efficacy, leading to delays or discontinuation of development programs.
  • Market Dependence: As a clinical-stage company, Kura does not yet generate significant revenue and relies on external funding.
  • Competition: The biopharmaceutical industry is highly competitive, and Kura faces competition from larger companies with greater resources.
  • Supply Chain Disruptions: The company’s operations could be affected by disruptions in the supply chain for raw materials and manufacturing.

Recent Developments

Kura Oncology has made significant progress in advancing its pipeline and corporate strategy:

  • Clinical Trial Updates: The company recently announced positive interim results from its Phase 2 trial of Tipifarnib in HRAS-mutant HNSCC, demonstrating strong clinical activity and durability.
  • KO-539 Progress: Kura has initiated a Phase 1/2 clinical trial for KO-539 in AML, with early data showing promising efficacy and safety.
  • Corporate Partnerships: Kura has entered into strategic collaborations to enhance its R&D capabilities and accelerate drug development.
  • COVID-19 Impact: The company has implemented measures to mitigate the impact of the COVID-19 pandemic on its operations and clinical trials.

Investment Considerations

Investors considering Kura Oncology should weigh the following factors:

Strengths

  • Strong focus on precision medicine and targeted therapies.
  • Promising clinical pipeline with multiple candidates in advanced stages of development.
  • Experienced leadership team and scientific advisory board.
  • Strategic partnerships and collaborations to enhance capabilities.

Risks

  • Dependence on external funding and lack of significant revenue.
  • Regulatory and clinical trial risks.
  • Competition from larger biopharmaceutical companies.
  • Market volatility and economic uncertainties.

Conclusion

Kura Oncology is a leading player in the field of precision oncology, with a strong pipeline of targeted therapies and a commitment to addressing unmet medical needs in cancer. While the company faces risks associated with clinical development and market competition, its innovative approach and strategic focus position it for long-term growth. As Kura advances its pipeline and expands its global presence, it has the potential to deliver significant value to patients and investors alike.